Short Interest in Clene Inc. (NASDAQ:CLNNW) Grows By 42.0%

Clene Inc. (NASDAQ:CLNNW) was the target of a significant growth in short interest in October. As of October 15th, there was short interest totalling 7,100 shares, a growth of 42.0% from the September 30th total of 5,000 shares. Based on an average daily trading volume, of 7,000 shares, the days-to-cover ratio is currently 1.0 days.

Clene Trading Down 34.8 %

Clene stock traded down $0.02 during mid-day trading on Tuesday, hitting $0.03. The company’s stock had a trading volume of 7,600 shares, compared to its average volume of 10,807. Clene has a twelve month low of $0.02 and a twelve month high of $0.09. The stock’s fifty day moving average price is $0.04 and its two-hundred day moving average price is $0.04.

Clene Company Profile

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.